Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 1
1992 6
1993 7
1994 12
1995 17
1996 20
1997 26
1998 23
1999 31
2000 31
2001 57
2002 54
2003 53
2004 56
2005 49
2006 59
2007 58
2008 59
2009 64
2010 69
2011 68
2012 65
2013 86
2014 60
2015 56
2016 58
2017 65
2018 50
2019 66
2020 73
2021 43
Text availability
Article attribute
Article type
Publication date

Search Results

1,320 results
Results by year
Filters applied: . Clear all
Page 1
Biomarkers for PTLD diagnosis and therapies.
Martinez OM. Martinez OM. Pediatr Nephrol. 2020 Jul;35(7):1173-1181. doi: 10.1007/s00467-019-04284-w. Epub 2019 Jun 25. Pediatr Nephrol. 2020. PMID: 31240394 Review.
The majority of PTLD are associated with Epstein Barr virus (EBV) and the characteristic EBV+ B cell lymphomas are the leading post-transplant malignancy in children. EBV+ PTLD remains a formidable issue in pediatric transplantation and is thoug …
The majority of PTLD are associated with Epstein Barr virus (EBV) and the characteristic EBV+ B cell lymphomas are the …
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Allen UD, et al. Clin Transplant. 2019 Sep;33(9):e13652. doi: 10.1111/ctr.13652. Epub 2019 Jul 23. Clin Transplant. 2019. PMID: 31230381
Recent epidemiologic studies report a decrease in early EBV-positive (+) PTLD and an increase in late EBV-negative (-) PTLD. Pre-transplant EBV-seronegativity and primary EBV infection, often from donor-transmitted infection, are an impor …
Recent epidemiologic studies report a decrease in early EBV-positive (+) PTLD and an increase in late EBV-negative (-) …
Epstein-Barr Virus: Clinical Diagnostics.
Niller HH, Bauer G. Niller HH, et al. Methods Mol Biol. 2017;1532:33-55. doi: 10.1007/978-1-4939-6655-4_2. Methods Mol Biol. 2017. PMID: 27873265 Review.
The vast majority of the human adult population is infected with Epstein-Barr virus (EBV), and the majority of the EBV-infected individuals tolerates the infection well, without any further symptoms after primary infection. ...However, the direct and quantita …
The vast majority of the human adult population is infected with Epstein-Barr virus (EBV), and the majority of the EBV- …
Epstein-Barr virus infection and posttransplant lymphoproliferative disorder.
Green M, Michaels MG. Green M, et al. Am J Transplant. 2013 Feb;13 Suppl 3:41-54; quiz 54. doi: 10.1111/ajt.12004. Am J Transplant. 2013. PMID: 23347213 Free article. Review.
EBV disease and its associated PTLD is more frequently seen when primary EBV infection occurs after transplant, a common scenario in pediatric SOT recipients. Intensity of immunosuppressive therapies also influences the risk for PTLD. The use of EBV
EBV disease and its associated PTLD is more frequently seen when primary EBV infection occurs after transplant, a commo
Epstein-Barr virus and renal transplantation.
Le J, Durand CM, Agha I, Brennan DC. Le J, et al. Transplant Rev (Orlando). 2017 Jan;31(1):55-60. doi: 10.1016/j.trre.2016.12.001. Epub 2016 Dec 29. Transplant Rev (Orlando). 2017. PMID: 28089555 Review.
Epstein-Barr virus (EBV) is a gamma herpesvirus associated with diseases ranging from asymptomatic viremia to post-transplant malignancies in kidney transplant recipients. EBV specifically is associated with post-transplantation lymphoproliferative disorder ( …
Epstein-Barr virus (EBV) is a gamma herpesvirus associated with diseases ranging from asymptomatic viremia to post-transplant …
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB. Van Besien K, et al. Leuk Lymphoma. 2019 Jul;60(7):1693-1696. doi: 10.1080/10428194.2018.1543877. Epub 2019 Feb 10. Leuk Lymphoma. 2019. PMID: 30741059
Among 147 patients who did not receive rituximab, the cumulative incidence of post-transplant EBV reactivation and of EBV PTLD was 13% and 8%, respectively. Among 51 who received pre-transplant rituximab, the incidences were 2% (p = .0017) and 0% (p = .04), r …
Among 147 patients who did not receive rituximab, the cumulative incidence of post-transplant EBV reactivation and of EBV P
Post-transplant lymphoproliferative disorders.
Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Dharnidharka VR, et al. Nat Rev Dis Primers. 2016 Jan 28;2:15088. doi: 10.1038/nrdp.2015.88. Nat Rev Dis Primers. 2016. PMID: 27189056 Review.
Recipient EBV seronegativity and the intensity of immunosuppression are among key risk factors. ...Diagnosis requires histopathology, although imaging techniques can provide additional supportive evidence. Pre-emptive intervention based on monitoring EBV levels in b …
Recipient EBV seronegativity and the intensity of immunosuppression are among key risk factors. ...Diagnosis requires histopathology, …
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Naik S, et al. Transpl Infect Dis. 2019 Oct;21(5):e13145. doi: 10.1111/tid.13145. Epub 2019 Jul 31. Transpl Infect Dis. 2019. PMID: 31301099 Free PMC article.
Although most PTLD is EBV-positive (EBV(pos) ), EBV-negative (EBV(neg) ) PTLD is reported, yet its incidence and clinical impact remain largely undefined. ...Clinical features and histology did not significantly differ among EBV(po …
Although most PTLD is EBV-positive (EBV(pos) ), EBV-negative (EBV(neg) ) PTLD is reported, yet its …
The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM, Krams SM. Martinez OM, et al. Transplantation. 2017 Sep;101(9):2009-2016. doi: 10.1097/TP.0000000000001767. Transplantation. 2017. PMID: 28376031 Free PMC article. Review.
The incidence of EBV+ PTLD is variable depending on the organ transplanted and whether the recipient has preexisting immunity to EBV but can be as high as 20%. ...We review the strategies that EBV uses to subvert and evade host immunity and discuss the …
The incidence of EBV+ PTLD is variable depending on the organ transplanted and whether the recipient has preexisting immunity …
1,320 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page